Safety profile of incobotulinum toxin A [Xeomin(®)] in gastrocnemious muscles injections in children with cerebral palsy: Randomized double-blind clinical trial.

[1]  I. Novak,et al.  A systematic review of interventions for children with cerebral palsy: state of the evidence , 2013, Developmental medicine and child neurology.

[2]  F. Panza,et al.  Safety and efficacy of incobotulinum toxin type A (NT 201-Xeomin) for the treatment of post-stroke lower limb spasticity: a prospective open-label study. , 2013, European journal of physical and rehabilitation medicine.

[3]  G. Logroscino,et al.  Efficacy and safety of higher doses of botulinum toxin type A NT 201 free from complexing proteins in the upper and lower limb spasticity after stroke , 2013, Journal of Neural Transmission.

[4]  J. Skranes,et al.  Botulinum neurotoxin treatment in children with cerebral palsy: a population-based study in Norway. , 2012, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[5]  Silvia Moguel-Ancheita,et al.  Neurorrehabilitación visual de pacientes con daño cerebral usando toxina botulínica , 2012 .

[6]  S. Hesse,et al.  An early botulinum toxin A treatment in subacute stroke patients may prevent a disabling finger flexor stiffness six months later: a randomized controlled trial , 2012, Clinical rehabilitation.

[7]  F. Panza,et al.  Effect of botulinum toxin type A and modified constraint-induced movement therapy on motor function of upper limb in children with obstetrical brachial plexus palsy , 2011, Child's Nervous System.

[8]  R. Goldman,et al.  Use of botulinum toxin A in management of children with cerebral palsy. , 2011, Canadian family physician Medecin de famille canadien.

[9]  T. Platz,et al.  Efficacy and safety of treatment with incobotulinum toxin A (botulinum neurotoxin type A free from complexing proteins; NT 201) in post-stroke upper limb spasticity. , 2011, Journal of rehabilitation medicine.

[10]  M. Waugh,et al.  Adverse events and health status following botulinum toxin type A injections in children with cerebral palsy , 2011, Developmental medicine and child neurology.

[11]  U. Narayanan.  Botulinum toxin: does the black box warning justify change in practice? , 2011, Developmental medicine and child neurology.

[12]  M. Barnes,et al.  Efficacy and safety of NT 201 for upper limb spasticity of various etiologies – a randomized parallel‐group study , 2010, Acta neurologica Scandinavica.

[13]  S. Apkon,et al.  Safety Considerations in the Use of Botulinum Toxins in Children With Cerebral Palsy , 2010, PM & R : the journal of injury, function, and rehabilitation.

[14]  T. Platz,et al.  Efficacy and Safety of Botulinum Neurotoxin NT 201 in Poststroke Upper Limb Spasticity , 2009, Clinical neuropharmacology.

[15]  A. Idrovo,et al.  Safety of botulinum toxin type A among children with spasticity secondary to cerebral palsy: a systematic review of randomized clinical trials , 2009, Clinical rehabilitation.

[16]  G. Molenaers,et al.  Safety and efficacy of botulinum toxin type A following long‐term use , 2006, European journal of neurology.

[17]  K. Desloovere,et al.  European consensus table 2006 on botulinum toxin for children with cerebral palsy. , 2006, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[18]  W. Jost,et al.  Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available botulinum toxin type A (BOTOX°) in healthy volunteers , 2005, Journal of Neural Transmission.

[19]  K. Aoki,et al.  Pharmacology and immunology of botulinum toxin type A. , 2003, Clinics in dermatology.

[20]  A. Bakheit.  Botulinum toxin in the management of childhood muscle spasticity: comparison of clinical practice of 17 treatment centres , 2003, European journal of neurology.

[21]  J. Jankovic,et al.  Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia , 2003, Neurology.

[22]  R. D'Agostino,et al.  Non‐inferiority trials: design concepts and issues – the encounters of academic consultants in statistics , 2002, Statistics in medicine.

[23]  L. A. Koman,et al.  Management of Cerebral Palsy with Botulinum‐A Toxin: Preliminary Investigation , 1993, Journal of pediatric orthopedics.

[24]  W. Jost,et al.  Botulinum Neurotoxin Type A Free of Complexing Proteins (XEOMIN®) in Focal Dystonia , 2012, Drugs.

[25]  K. Desloovere,et al.  The updated European Consensus 2009 on the use of Botulinum toxin for children with cerebral palsy. , 2010, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.